Fig 3. Increased percentages of CD3^-CD8^dullCD56⁺ and CD3^-CD8^dullCD56⁺ILT2⁺GAD65 AA 114–122 pentamer reactive cells in T1D patients.

Relative percentages of CD3^-CD8^dullCD56⁺ and CD3^-CD8^dullCD56⁺ILT2⁺ GAD65 AA 114–122 pentamer reactive cells in T1D patients vs healthy controls after GAD65 peptide stimulation. (A) Representative experiment showing the flow-cytometry gate strategy; (B) Summary of results of CD3^-CD8^dullCD56⁺ GAD65 AA 114–122 pentamer reactive cells obtained in 15 healthy donors (circle dots) and 15 T1D patients (square dots); (C) Summary of results of CD3^-CD8^dullCD56⁺ ILT2⁺ GAD65 AA 114–122 pentamer reactive cells. Horizontal bars, average values are reported.